Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Dr. Sanjiv Patel, will deliver a presentation on Tuesday, January 14, 2025, at 7:30 a.m. PT.
The presentation will be accessible through a live webcast on the company's website under the Events section in News & Events. Interested parties can access the webcast through the IR portal at ir.relaytx.com. An archived version of the presentation will remain available for 30 days after the event.
Relay Therapeutics specializes in transforming drug discovery by combining advanced computational and experimental technologies.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT.
The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When is Relay Therapeutics (RLAY) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access Relay Therapeutics' (RLAY) J.P. Morgan Healthcare Conference presentation?
How long will Relay Therapeutics' (RLAY) J.P. Morgan presentation replay be available?
What is Relay Therapeutics' (RLAY) approach to drug discovery?
